A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Tianjin Medical University Cancer Institute and Hospital
Seagen Inc.
Peking University
Bold Therapeutics, Inc.
Sun Yat-sen University
TransThera Sciences (Nanjing), Inc.
AIO-Studien-gGmbH
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Toray Industries, Inc
First Affiliated Hospital of Zhejiang University
Lisata Therapeutics, Inc.
West China Hospital
Harbin Medical University
CSPC Ouyi Pharmaceutical Co., Ltd.
University of Chicago
University of Cincinnati
Khon Kaen University
Sun Yat-sen University
Benaroya Research Institute
The Christie NHS Foundation Trust
Sun Yat-sen University
National Cancer Institute (NCI)
Galectin Therapeutics Inc.
Peking University
Stanford University
University of Utah